MetaCap

MIRA Pharmaceuticals (MIRA) vs Neuphoria Therapeutics (NEUP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neuphoria Therapeutics (NEUP) has outperformed MIRA Pharmaceuticals (MIRA) over the past year, losing 47.3% versus a loss of 79.1%. Neuphoria Therapeutics is the larger company by market cap ($12.7 million vs $12.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIRA-79.06%NEUP-47.31%
+28%-28%-84%
Nov 21, 20251 yearNov 20, 2026
MIRA-95.16%NEUP-86.77%
+184%+38%-108%
Jul 31, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIRA versus NEUP key metrics
MetricMIRANEUP
Share price$0.291$2.35
Market cap$12.23M$12.72M
1-day change-20.84%+1.29%
YTD return-80.73%-39.43%
1-year return-79.06%-47.31%
P/E ratio (TTM)29.10—
EPS (TTM)$0.01$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.17M
Revenue growth (YoY)—-92.50%
Net income (latest FY)$-10.44M$-13.45M
Operating margin—-1401.09%
Net margin—-1145.66%
52-week high$1.69$5.53
52-week low$0.255$2.26
Distance from 52-week high-82.78%-57.50%
Analyst consensusnonenone
Avg. price target upside+1102.75%—
Average volume622.02K26.53K
Shares outstanding42.02M5.41M
Employees—1
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NEUP has outperformed MIRA by 31.8 percentage points over the past year.

About MIRA Pharmaceuticals

MIRA stock →

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.

Health Care · Biotechnology: Pharmaceutical Preparations

About Neuphoria Therapeutics

NEUP stock →

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

MIRA vs NEUP FAQ

Which is bigger, MIRA Pharmaceuticals or Neuphoria Therapeutics?

Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $12.72M compared with $12.23M for MIRA Pharmaceuticals (MIRA).

Which stock has performed better over the past year, MIRA or NEUP?

NEUP returned -47.31% over the past 12 months, compared with -79.06% for MIRA (price return, excluding dividends). Past performance does not predict future results.

Are MIRA Pharmaceuticals and Neuphoria Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons